European Neurology
Original Paper
Carotid Intima-Media Thickness in HIV-Infected Individuals: Relationship of Premature Atherosclerosis to Neuropsychological Deficits?Yaldizli Ö.a · Kastrup O.a · Obermann M.a · Esser S.b · Wilhelm H.a · Ley C.a · Diener H.-C.a · Maschke M.aDepartments of aNeurology and bDermatology, University of Duisburg-Essen, Essen, Germany
|
|
Log in to MyKarger to check if you already have access to this content.
KAB
Buy a Karger Article Bundle (KAB) and profit from a discount!
If you would like to redeem your KAB credit, please log in.
Save over 20% compared to the individual article price.
Article / Publication Details
Received: December 06, 2005
Accepted: March 23, 2006
Published online: June 23, 2006
Issue release date: June 2006
Number of Print Pages: 6
Number of Figures: 4
Number of Tables: 2
ISSN: 0014-3022 (Print)
eISSN: 1421-9913 (Online)
For additional information: https://www.karger.com/ENE
Abstract
Background: Intima-media thickness (IMT) measured by extracranial duplex sonography is a surrogate marker for atherosclerosis. It is well known that IMT is greater in HIV patients than in age-matched healthy controls due to HIV- induced endothelial damage and metabolic side-effects of antiretroviral therapy. However, it remains unclear whether atherosclerosis has an additional impact on cognitive function in HIV patients. Therefore, the objective of this study was to investigate the correlation between IMT and neuropsychological deficits in HIV patients. Methods: 47 HIV patients and 40 age-matched healthy controls were examined by extracranial ultrasound 2 and 3 cm before the flow divider to evaluate differences in IMT. Possible neuropsychological deficits in HIV patients were assessed using a battery of 10 neuropsychological tests. Results of neuropsychological tests and markers of disease severity were correlated with IMT in HIV patients. Results: IMT was significantly greater in patients than in healthy controls (p < 0.001). However, none of the neuropsychological tests correlated significantly with IMT measurements in HIV patients. There was only a weak correlation between deficits in attention and IMT in HIV patients (r = 0.44; p = 0.005), which was non-significant after correction for multiple comparisons. Markers of disease severity (CD4 cell count, HIV load in plasma, duration of HIV disease) did not correlate with IMT either. Conclusion: IMT was greater in HIV patients compared to age-matched controls but it appears that premature atherosclerosis has no additional impact on the evolution of neuropsychological deficits in HIV patients. IMT did not correlate with the severity of immunodeficiency.
© 2006 S. Karger AG, Basel
Related Articles:
References
- Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ, Holmberg SD: Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998;338:853–860.
- Maschke M, Kastrup O, Esser S, Ross B, Hengge U, Hufnagel A: Incidence and prevalence of neurological disorders associated with HIV since the introduction of highly active antiretroviral therapy (HAART). J Neurol Neurosurg Psychiatry 2000;69:376–380.
- Sacktor N, Lyles RH, Skolasky R, Kleeberger C, Selnes OA, Miller EN, Becker JT, Cohen B, McArthur JC, Multicenter AIDS Cohort Study: HIV-associated neurologic disease incidence changes: Multicenter AIDS Cohort Study, 1990–1998. Neurology 2001;56:257–260.
- Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA: Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999;353:2093–2099.
- Holmberg SD, Moorman AC, Williamson JM, Tong TC, Ward DJ, Wood KC, Greenberg AE, Janssen RS, HIV Outpatient Study (HOPS) investigators: Protease inhibitors and cardiovascular outcomes in patients with HIV-1. Lancet 2002;360:1747–1748.
- Stein JH, Klein MA, Bellehumeur JL, McBride PE, Wiebe DA, Otvos JD, Sosman JM: Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction. Circulation 2001;104:257–262.
- Chambless LE, Heiss G, Folsom AR, Rosamond W, Szklo M, Sharrett AR, Clegg LX: Association of coronary heart disease incidence with carotid arterial wall thickness and major risk factors: the Atherosclerosis Risk in Communities (ARIC) Study, 1987–1993. Am J Epidemiol 1997;146:483–494.
- Maggi P, Serio G, Epifani G, Fiorentino G, Saracino A, Fico C, Perilli F, Lillo A, Ferraro S, Gargiulo M, Chirianni A, Angarano G, Regina G, Pastore G: Premature lesions of the carotid vessels in HIV-1-infected patients treated with protease inhibitors. AIDS 2000;14:F123–128.
- Depairon M, Chessex S, Sudre P, Rodondi N, Doser N, Chave JP, Riesen W, Nicod P, Darioli R, Telenti A, Mooser V, Swiss HIV Cohort Study: Premature atherosclerosis in HIV-infected individuals – Focus on protease inhibitor therapy. AIDS 2001;15:329–334.
- Seminari E, Pan A, Voltini G, Carnevale G, Maserati R, Minoli L, Meneghetti G, Tinelli C, Testa S: Assessment of atherosclerosis using carotid ultrasonography in a cohort of HIV-positive patients treated with protease inhibitors. Atherosclerosis 2002;162:433–438.
- Mercie P, Thiebaut R, Lavignolle V, Pellegrin JL, Yvorra-Vives MC, Morlat P, Ragnaud JM, Dupon M, Malvy D, Bellet H, Lawson-Ayayi S, Roudaut R, Dabis F: Evaluation of cardiovascular risk factors in HIV-1 infected patients using carotid intima-media thickness measurement. Ann Med 2002;34:55–63.
- Chironi G, Escaut L, Gariepy J, Cogny A, Teicher E, Monsuez JJ, Levenson J, Simon A, Vittecoq D: Brief report: carotid intima-media thickness in heavily pretreated HIV-infected patients. J Acquir Immune Defic Syndr 2003;32:490–493.
- Mercie P, Thiebaut R, Aurillac-Lavignolle V, Pellegrin JL, Yvorra-Vives M, Cipriano C, Neau D, Morlat P, Ragnaud J, Dupon M, Bonnet F, Lawson-Ayayi S, Malvy D, Roudaut R, Dabis F, on behalf of the Groupe d’Epidemiologie Clinique du Sida en Aquitaine (GECSA): Carotid intima-media thickness is slightly increased over time in HIV-1-infected patients. HIV Med 2005;6:380–387.
- Johnston SC, O’Meara ES, Manolio TA, Lefkowitz D, O’Leary DH, Goldstein S, Carlson MC, Fried LP, Longstreth WT Jr: Cognitive impairment and decline are associated with carotid artery disease in patients without clinically evident cerebrovascular disease. Ann Intern Med 2004;140:237–247.
- Zheng J, Gendelman HE: The HIV-1 associated dementia complex: a metabolic encephalopathy fueled by viral replication in mononuclear phagocytes. Curr Opin Neurol 1997;10:319–325.
- Markus HS, Sitzer M, Carrington D, Mendall MA, Steinmetz H: Chlamydiapneumoniae infection and early asymptomatic carotid atherosclerosis. Circulation 1999;100:832–837.
- Talelli P, Ellul J, Terzis G, Lekka NP, Gioldasis G, Chrysanthopoulou A, Papapetropoulos T: Common carotid artery intima media thickness and post-stroke cognitive impairment. J Neurol Sci 2004;223:129–134.
- Hsue PY, Lo JC, Franklin A, Bolger AF, Martin JN, Deeks SG, Waters DD: Progression of atherosclerosis as assessed by carotid intima-media thickness in patients with HIV infection. Circulation 2004;109:1603–1608.
- Bozzette SA, Ake CF, Tam HK, Chang SW, Louis TA: Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N Engl J Med 2003;348:702–710.
Article / Publication Details
Received: December 06, 2005
Accepted: March 23, 2006
Published online: June 23, 2006
Issue release date: June 2006
Number of Print Pages: 6
Number of Figures: 4
Number of Tables: 2
ISSN: 0014-3022 (Print)
eISSN: 1421-9913 (Online)
For additional information: https://www.karger.com/ENE
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
Get Permission
PubMed ID
